Surgical treatment of medication-related osteonecrosis of the jaw in patients with autoimmune diseases
10.21851/obr.48.02.202406.45
- Author:
Young Hoon KANG
1
;
Na Young LEE
Author Information
1. Associate Professor, Department of Dentistry, Institute of Medical Science, Gyeongsang National University School of Medicine, Jinju, Republic of Korea
- Publication Type:Original Article
- From:
Oral Biology Research
2024;48(2):45-51
- CountryRepublic of Korea
- Language:English
-
Abstract:
This retrospective, single-center study compares the factors influencing the surgical outcomes of medication-related osteonecrosis of the jaw (MRONJ) in patients with and without autoimmune diseases (AIDs). The total surgical success rate was 92% during the mean 2-year follow-up period, and treatment failure was observed in 8% of all patients without AID and 12% of patients with AIDs. Bisphosphonate duration and administration route (intravenous) were found to be risk factors of MRONJ. A careful treatment plan should be developed with a multidisciplinary team including a rheumatologist and a maxillofacial surgeon to avoid the use of drugs that may adversely affect treatment results when MRONJ occurs in patients with AIDs.
